Skip to main content
Premium Trial:

Request an Annual Quote

Rigel Licenses Cyclic Peptide Library and Novel Protein from Two Research Groups

NEW YORK, Feb. 21 - Functional-genomics firm Rigel Pharmaceuticals has made two new licensing deals with academic researchers at Pennsylvania State University and the Oklahoma Medical Research Foundation, the company said on Thursday.


From Penn State, Rigel has in-licensed Siclopps, the cyclic peptide technology. The company is developing its own intracellular cyclic peptide library, which it plans to integrate with its functional-genomics system as a source of potential new therapeutics.


From the Oklahoma foundation, the company in-licensed the patent to the RBX protein. Also known as ROC1, this protein is a ubiquitin ligase with potential therapeutic relevance to both oncology and inflammatory disease, two areas in which Rigel is interested. The company has already begun high-throughput screening with this target.


The Oklahoma Medical Research Foundation is a private non-profit biomedical research center based in Oklahoma City.


Rigel Pharmaceuticals, of South San Francisco, Calif., hopes to begin clinical trials this year on one or more new drugs for inflammatory disease, cancer, or hepatitis C.


In early September, the company launched a two-year structural-proteomics collaboration with MediChem focused on ubiquitin ligases.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.